888-969-2592
Kalkine 0
countryflagCA

Medipharm Labs Corp

Healthcare CA LABS

0.09CAD
-0.005(5.26%)

Last update at 2025-05-09T15:28:00Z

Day Range

0.090.09
LowHigh

52 Week Range

0.060.10
LowHigh

Fundamentals

  • Previous Close 0.10
  • Market Cap28.77M
  • Volume120300
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-4.94500M
  • Revenue TTM37.76M
  • Revenue Per Share TTM0.09
  • Gross Profit TTM -13.42000M
  • Diluted EPS TTM-0.04

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -29.98900M -54.68800M -72.10000M 6.75M -8.46600M
Minority interest - 0.00000M 0.76M -0.32000M 0.19M
Net income -29.98300M -54.80100M -67.11000M 1.13M -8.41100M
Selling general administrative 18.45M 18.40M 24.59M 30.86M 5.54M
Selling and marketing expenses 6.30M 4.63M 4.37M 3.33M 1.27M
Gross profit -1.91400M -15.24600M -43.97800M 42.91M 3.97M
Reconciled depreciation 2.87M 5.63M 10.81M 2.53M 0.98M
Ebit -29.53300M -48.91600M -72.57600M 6.94M -8.02700M
Ebitda -25.44000M -37.15100M -59.94800M 9.96M -7.09500M
Depreciation and amortization 4.09M 11.77M 12.63M 3.02M 0.93M
Non operating income net other - - - - -
Operating income -29.53300M -48.91600M -72.57600M 6.94M -8.02700M
Other operating expenses 50.91M 64.72M 107.04M 122.31M 18.23M
Interest expense 0.03M 10.51M 7.88M 0.67M 0.36M
Tax provision -0.00600M 0.11M -4.99000M 5.62M -
Interest income 0.46M 5.77M 7.56M 0.19M 0.28M
Net interest income 0.45M -10.28100M -7.60200M -0.18600M -0.41400M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -0.00600M 0.11M -4.99000M 5.62M -0.05500M
Total revenue 22.12M 21.71M 36.01M 129.25M 10.20M
Total operating expenses 26.88M 27.76M 27.05M 35.98M 11.99M
Cost of revenue 24.03M 36.96M 79.99M 86.34M 6.23M
Total other income expense net -0.45600M -5.77200M 0.48M -0.18600M -0.43900M
Discontinued operations - - - - -
Net income from continuing ops -29.98300M -54.80100M -67.11000M 1.13M -8.46600M
Net income applicable to common shares -29.98300M -54.80100M -66.35300M 1.65M -8.38600M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 63.94M 65.50M 92.36M 118.23M 168.83M
Intangible assets 1.03M 0.04M 0.04M 0.23M -
Earning assets - - - - -
Other current assets 2.89M 2.27M 4.75M 4.59M 2.05M
Total liab 10.93M 9.49M 9.21M 39.82M 37.60M
Total stockholder equity 53.01M 56.01M 83.15M 78.41M 131.55M
Deferred long term liab - - - - -
Other current liab 6.39M 4.00M 4.45M 19.99M 7.97M
Common stock 200.24M 191.26M 190.55M 138.51M 122.81M
Capital stock 200.24M 191.26M 190.55M 138.51M 122.81M
Retained earnings -176.73200M -163.64900M -129.34300M -74.54200M -8.18900M
Other liab - - 0.23M 4.81M -
Good will - - - - -
Other assets 0.00000M 0.00000M 0.88M 2.15M 6.71M
Cash 17.98M 24.14M 34.11M 19.91M 38.63M
Cash and equivalents - 24.14M 34.11M 19.91M 38.63M
Total current liabilities 10.86M 9.46M 8.88M 24.25M 28.85M
Current deferred revenue 0.11M 1.32M 1.32M 1.00M -
Net debt -15.68600M -23.51300M -33.89400M -1.45500M -28.04700M
Short term debt 2.23M 0.60M 0.11M 7.70M 1.82M
Short long term debt 2.10M 0.52M - 7.38M 1.46M
Short long term debt total 2.29M 0.63M 0.22M 18.46M 10.58M
Other stockholder equity - 0.00000M 21.94M 14.45M 16.93M
Property plant equipment - 18.11M 25.89M 34.14M 42.23M
Total current assets 36.63M 47.34M 65.55M 81.52M 119.70M
Long term investments - - 0.00000M 0.19M 0.19M
Net tangible assets - - 83.10M 78.19M 131.55M
Short term investments 0.27M - - - 0.00000M
Net receivables 5.87M 13.15M 17.35M 34.88M 27.54M
Long term debt - - 0.00000M 10.54M 8.12M
Inventory 9.90M 7.78M 10.98M 22.14M 51.49M
Accounts payable 2.13M 3.54M 2.99M 5.55M 19.06M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 29.49M 28.40M 21.94M 14.45M 16.93M
Additional paid in capital - - - - -
Common stock total equity - - - 138.51M 122.81M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 1.00M - 0.88M 2.10M 6.12M
Deferred long term asset charges - - - - -
Non current assets total 27.30M 18.15M 26.81M 36.71M 49.13M
Capital lease obligations 0.19M 0.11M 0.22M 0.54M 1.00M
Long term debt total - 0.03M 0.10M 10.76M 8.76M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 5.16M 0.04M -0.00200M -32.54600M -14.60300M
Change to liabilities - -8.10700M -4.57000M 11.24M 6.88M
Total cashflows from investing activities 5.16M 0.04M -7.44600M -32.54600M -14.60300M
Net borrowings - -2.96200M 22.08M 3.50M 6.00M
Total cash from financing activities 0.80M 27.80M 26.42M 88.50M 31.06M
Change to operating activities - 1.79M -1.07600M 0.16M -2.27900M
Net income -29.98300M -54.80100M -67.11000M 1.13M -8.46600M
Change in cash -9.96500M 14.20M -18.71400M 30.78M 5.36M
Begin period cash flow 34.11M 19.91M 38.63M 7.85M 2.49M
End period cash flow 24.14M 34.11M 19.91M 38.63M 7.85M
Total cash from operating activities -16.06900M -13.21300M -37.77300M -25.26500M -11.11300M
Issuance of capital stock 0.00000M 30.92M - 70.83M 0.16M
Depreciation 2.87M 5.63M 10.81M 2.53M 0.98M
Other cashflows from investing activities 6.02M 0.82M 0.06M -0.10800M -0.03100M
Dividends paid 0.00000M 0.00000M 0.00000M 0.00000M -
Change to inventory -0.10300M 11.16M 29.41M -42.08200M -9.40400M
Change to account receivables 3.62M 12.73M -2.08900M -21.07500M -6.42700M
Sale purchase of stock 0.00000M 30.92M 5.31M 85.31M 0.16M
Other cashflows from financing activities 1.74M -0.15100M 40.48M 23.87M 6.77M
Change to netincome - 14.13M 0.71M 20.80M 7.52M
Capital expenditures 0.86M 0.78M 7.50M 32.44M 14.57M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 6.25M 21.83M 17.06M -50.23600M -11.22500M
Stock based compensation 2.87M 2.40M 2.68M 15.50M 1.97M
Other non cash items 1.93M 11.61M 3.66M 0.19M 5.63M
Free cash flow -16.93200M -13.99600M -45.27600M -57.70300M -25.68500M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (CAD) Price (CAD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
LABS
Medipharm Labs Corp		 -0.005 5.26% 0.09 - 27.47 0.76 0.60 0.41 -1.8196
BHC
Bausch Health Companies Inc		 -0.14 2.13% 6.42 - 2.23 0.50 18.74 2.56 9.13
CURA
Curaleaf Holdings Inc.		 -0.05 4.13% 1.16 - 138.89 1.62 1.66 1.73 10.18
TLRY
Tilray Inc		 -0.01 1.64% 0.60 - 1000.00 2.17 0.36 1.69 -2.299
CRON
Cronos Group Inc		 0.01 0.54% 2.79 - - 10.18 0.70 0.02 -1.9458

Reports Covered

Stock Research & News

View All

Profile

MediPharm Labs Corp., a pharmaceutical company, engages in the production and sale of purified, pharmaceutical-quality cannabis extracts, concentrates, active pharmaceutical ingredients, and advanced derivative products in Canada, Australia, Germany, and internationally. The company formulates, processes, packages, and distributes cannabis active ingredients and advanced cannabinoid-based products. It also provides good manufacturing practice flower sourcing, packaging, and distribution services, as well as dried flower and pre-roll cannabis products. In addition, the company offers cannabis related medical information and services; and medical cannabis clinic services. MediPharm Labs Corp. was founded in 2015 and is headquartered in Barrie, Canada.

Medipharm Labs Corp

151 John Street, Barrie, ON, Canada, L4N 2L1

Key Executives

Name Title Year Born
Mr. Keith Strachan Co-Founder & Pres NA
Mr. Greg Hunter Chief Financial Officer NA
Mr. David A. Pidduck CEO & Director NA
Mr. Patrick McCutcheon Founder NA
Mr. Saravan Subramaniam VP of Operations & Supply Chain NA
Mr. Geoffrey Marr Exec. VP & Gen. Counsel NA
Mr. Brett Moon VP of Sales NA
Mr. Kirk Binns Exec. VP of Global Accounts NA
Mr. Nigel Dewsbury Head of Quality NA
Mr. Keith Strachan Co-Founder & President NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.